Rhumbline Advisers cut its holdings in Bruker Co. (NASDAQ:BRKR) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 107,074 shares of the medical research company’s stock after selling 2,665 shares during the quarter. Rhumbline Advisers owned approximately 0.07% of Bruker worth $3,185,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. AJO LP acquired a new position in shares of Bruker during the 2nd quarter worth approximately $46,075,000. First Trust Advisors LP increased its holdings in shares of Bruker by 1,689.7% during the 3rd quarter. First Trust Advisors LP now owns 502,159 shares of the medical research company’s stock worth $14,939,000 after acquiring an additional 474,101 shares during the last quarter. Prudential Financial Inc. increased its holdings in shares of Bruker by 292.8% during the 3rd quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock worth $16,868,000 after acquiring an additional 422,660 shares during the last quarter. Koch Industries Inc. boosted its stake in Bruker by 2,573.5% in the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after purchasing an additional 322,252 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Bruker during the 2nd quarter valued at $6,806,000. Institutional investors own 65.63% of the company’s stock.

In related news, VP Mark Munch sold 21,061 shares of Bruker stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the sale, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 35.20% of the stock is currently owned by company insiders.

Bruker Co. (NASDAQ:BRKR) opened at $34.82 on Friday. Bruker Co. has a fifty-two week low of $21.03 and a fifty-two week high of $36.53. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $5,318.69, a P/E ratio of 29.22, a PEG ratio of 2.89 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The company had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. During the same period last year, the business posted $0.32 earnings per share. Bruker’s revenue was up 10.6% on a year-over-year basis. sell-side analysts forecast that Bruker Co. will post 1.19 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 22nd. Investors of record on Monday, December 4th will be paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.46%. The ex-dividend date is Friday, December 1st. Bruker’s dividend payout ratio is 17.02%.

Several analysts recently weighed in on the company. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Goldman Sachs Group reaffirmed a “sell” rating and issued a $24.00 target price on shares of Bruker in a report on Tuesday, September 26th. J P Morgan Chase & Co raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a report on Friday, November 3rd. Cowen reissued a “hold” rating and issued a $29.00 price target on shares of Bruker in a research note on Friday, November 3rd. Finally, Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price target for the company in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $29.64.

ILLEGAL ACTIVITY NOTICE: “Bruker Co. (BRKR) Holdings Cut by Rhumbline Advisers” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/09/bruker-co-brkr-holdings-cut-by-rhumbline-advisers.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Stock Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related stocks with our FREE daily email newsletter.